SCTXScribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on ca…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Norwegian Cruise downgrade, Duolingo upgraded: Wall Street's top analyst calls Norwegian Cruise downgrade, Duolingo upgraded: Wall Street's top analyst calls | TThe Fly | |
 Scribe’s Genetic Editing Aims to Prevent Heart Attacks Scribe Therapeutics shares are up 30% since it raised $125 million in its initial public offering Friday. The cash will fund three clinical trials testing whether Scribe’s one-time treatments can halve the risk of heart attacks and strokes. Scribe’s therapies turn off the genetic instructions leading to high levels of damaging lipids, without having to cut a gene’s DNA strands like other one-shot genetic treatments in the clinic. | ||
Scribe Therapeutics Soars 67% After $128.7 Million Upsized IPO Gene-editing biotech debuts at $25, backed by Sanofi and Eli Lilly, with a roughly $440.3 million valuation. | ||